New & Noteworthy

Sep 06, 2017
Pharmaceutical Executive
Cynthia Schwalm, EVP and president of North American commercial operations for Ipsen, talks to Pharm Exec about the importance of stepping outside of the C-suite and into the world of the patient.
Sep 05, 2017
Pharmaceutical Executive
The time is now for pharma to take next steps in tech adoption, writes Lance Scott.
Sep 05, 2017
Neil Grubert reviews the UK’s post-Brexit life sciences strategy, with a particular focus on the key area of market access.
Sep 05, 2017
For marketers, getting messages out in the age of polarization and "TMI" requires common sense and courage, says Al Topin.
Sep 04, 2017
Lisa Kerber outlines how the pharma industry can take advantage of combining new clinical data sources such as diagnostics, or lab data, with AI to deliver on the promise of improving outcomes.
Sep 04, 2017
Jeremy Schafer & Deborah Lotterman discuss the impact of financial toxicity on patients and payers and outline the strategies needed to begin to remedy it.
Sep 04, 2017
As regulators lower evidentiary requirements for approval to speed development/review of new drugs for unmet medical needs, payers are demanding more data to justify price premiums. How can companies can navigate these complexities?
Aug 28, 2017
The federal Open Payments program is finally reaching its goal—to halt the adoption of multiple “transparency” initiatives. But will it make a difference, asks Jill Wechsler.
Aug 25, 2017
Pharmaceutical Executive
Experts assess the current pharma dealmaking landscape—one where, despite market headwinds, is still heavily influenced by factors under the buyer and seller’s control.
Aug 21, 2017
Pharmaceutical Executive
Four strategic takeaways from this year's event that are important for pharma oncology leaders, by Maria Whitman and Sharon Karlsberg.
native1_300x100
lorem ipsum